Marloes van Dongen

Marloes van Dongen is an internist-oncologist and clinical pharmacologist. She specializes in the treatment of breast cancer and the development of new drugs. Her scientific interest lies mainly in early phase clinical trials in which new therapies are investigated in patients for the first time (phase I and early phase II).

At the Netherlands Cancer Institute, she is part of both the breast cancer team and the early-stage clinical trials team at the Clinical Research Unit (CRU).

Marloes obtained her PhD at the Centre for Human Drug Research (CHDR) in Leiden, where she researched early-phase studies with antisense oligonucleotides. Since 2018, she has been working at the Netherlands Cancer Institute and is the principal investigator of a large number of clinical trials, both industrially sponsored and in-house research lines. In addition, she is co-author of various handbooks for both patients and doctors.

In addition to her clinical and scientific work, Marloes has been a member of the Oncological Drugs Assessment Committee (cieBOM) since the beginning of 2025. Since 2019, she has also been chair of the scientific committee of the annual Wadden Breast Cancer Days Workshop. From 2020 to 2025, she was a member of the editorial board of the journal Medical Oncology.

Specialism and interests

• Breast cancer treatment
• Early drug development and clinical trials
• Goal-oriented therapies
• Immunotherapy

Relevant committees/networks/other relevant experience

• Member of the National Committee for the Assessment of Oncological Drugs (cieBOM)
• Founder of the Dutch multi-day workshop on breast cancer
• Publications

See the list of publications by Marloes van Dongen: Marloes G.J. van Dongen (0009-0001-7822-9492) - ORCID